138 related articles for article (PubMed ID: 5517707)
1. [Clinical and plethysmographic evaluation in patients with peripheral arteriopathies treated with pyridinolcarbamate].
Lucero Eseverri JA; Fajardo JD; Velles Aguirre L; Quijano E; Ciliberti E; Lucarelli R
Prensa Med Argent; 1970 Apr; 57(8):394-8. PubMed ID: 5517707
[No Abstract] [Full Text] [Related]
2. Clinical pharmacologic evaluation of the antiatherosclerotic agent, pyridinolcarbamate. A double-blind crossover trial in the treatment of atherosclerosis obliterans.
Shimamoto T; Atsumi T; Yamashita S; Motomiya T; Isokane N; Ishioka T; Sakuma A
Am Heart J; 1970 Jan; 79(1):5-19. PubMed ID: 4903137
[No Abstract] [Full Text] [Related]
3. Pyridinolcarbamate treatment of atherosclerosis obliterans analysed by toe plethysmography.
Motomiya T; Atsumi T; Isokane N; Yamashita S; Sano T
Jpn Heart J; 1970 Sep; 11(5):433-49. PubMed ID: 4921577
[No Abstract] [Full Text] [Related]
4. [Treatment of arteriosclerotic peripheral chronic obliterating arteriopathies (A.P.C.O.) of the lower extremities with a new pharmacologic combination].
Bagliani A; Borri P; Parravicini R
Minerva Cardioangiol; 1975 Nov; 23(11):701-10. PubMed ID: 1223674
[No Abstract] [Full Text] [Related]
5. [Effect of pyridinol carbamate (Anginin) in peripheral arterial blood circulation disorders].
Heisig N; Westermann KW; Stolterfoht CA; Zaki J
Med Klin; 1970 Dec; 65(52):2289-93. PubMed ID: 5522670
[No Abstract] [Full Text] [Related]
6. Double-blind crossoer clinical trial of pyridinolcarbamate in peripheral arterial disease (arteriosclerosis obliterans).
Walton KW; Craig GM; Prior P; Waterhouse JA; Skilton J
Br Heart J; 1973 Feb; 35(2):211-9. PubMed ID: 4570447
[No Abstract] [Full Text] [Related]
7. [Clinical evaluation of pyridinolcarbamate effect on patients with obliterating atherosclerosis (author's transl)].
Roztocil K; Oliva I; Linhart J; Prerovský I; Modr Z
Cas Lek Cesk; 1976 Aug; 115(33-34):1051-5. PubMed ID: 975177
[No Abstract] [Full Text] [Related]
8. [Clinical tests using pyridinol carbamate on the arterial circulation and blood coagulation in patients with arteriosclerosis obliterans].
De Soldati L; Castro CM; Grilli H; Reussi J
Prensa Med Argent; 1969 May; 56(12):546-53. PubMed ID: 5343928
[No Abstract] [Full Text] [Related]
9. Treatment of atherosclerosis obliterans with pyridinolcarbamate.
Atsumi T; Motomiya T; Isokane N; Shimamoto T
Jpn Heart J; 1971 Jul; 12(4):335-46. PubMed ID: 5314713
[No Abstract] [Full Text] [Related]
10. [Effect of pyridinolcarbamate on blood coagulation and thrombolysis in patients with arteriosclerosis obliterans].
Hess H; Goossens N; Keil-Kuri E; Zollner R; Meyer A
Vasa; 1972; 1(3):206-11. PubMed ID: 5076123
[No Abstract] [Full Text] [Related]
11. [Evaluation of the action of p-chlorophenoxy alpha-isobutyrate of 3-hydroxymethyl pyridine hydrochloride on peripheral circulation. Rheographic and radioisotope studies].
Modica G; Ferrante R
Minerva Cardioangiol; 1973 Dec; 21(12):769-74. PubMed ID: 4592148
[No Abstract] [Full Text] [Related]
12. [Treatment of atherosclerosis by pyridinolcarbamate. Review of the history of the introduction of pyridinolcarbamate and its clinical results].
Shimamoto T
Rev Atheroscler (Paris); 1968; 10(3):67-84. PubMed ID: 5746502
[No Abstract] [Full Text] [Related]
13. The effect of pyridinolcarbamate after acute and chronic administration in patients with atherosclerosis obliterans.
Roztocil K; Oliva J; Linhart J; Prerovský I; Modr Z
Int J Clin Pharmacol Biopharm; 1977 Mar; 15(3):135-8. PubMed ID: 844932
[TBL] [Abstract][Full Text] [Related]
14. [A double blind crossover trial in pyridinolcarbamate treatment of atherosclerosis obliterans].
Yamashita S
Nihon Naika Gakkai Zasshi; 1969 Apr; 58(4):283-92. PubMed ID: 4896659
[No Abstract] [Full Text] [Related]
15. [Anginin (pyridinol carbamate) therapy of coronary atherosclerosis and obliterating atherosclerosis of the arteries of the lower extremities].
Liusov VA; Belousov IuB; Martynov AI; Koroleva SA; Zimin VS
Kardiologiia; 1972 Nov; 12(11):39-45. PubMed ID: 4655879
[No Abstract] [Full Text] [Related]
16. [Pyridinolcarbamate treatment of atherosclerosis obliterans analysed by toe plethysmography].
Motomiya T
Nihon Naika Gakkai Zasshi; 1970 Feb; 59(2):117-25. PubMed ID: 4910199
[No Abstract] [Full Text] [Related]
17. [On some aspects of therapy of chronic peripheral obliterating arteriopathies (C.P.O.A.) on arteriosclerotic nature].
Seghezzi R; Borri P; Pedroni G
Minerva Med; 1968 Dec; 59(99):5458-65. PubMed ID: 5718833
[No Abstract] [Full Text] [Related]
18. [Clinical, oscillographic and plethysmographic comparison before and after medical and surgical treatment of subjects with peripheral obliterating arteriopathy].
Tardito E; Grassi T
Minerva Med; 1971 May; 62(39):1971-80. PubMed ID: 5579735
[No Abstract] [Full Text] [Related]
19. Pyridinolcarbamate, bradykinin antagonist, in patients suffering from arteriosclerosis obliterans and thromboangiitis obliterans (Buerger's disease); a preliminary report on the treatment of human atherosclerosis.
Shimamoto T; Atsumi T
Jpn Heart J; 1965 Sep; 6(5):407-15. PubMed ID: 5294603
[No Abstract] [Full Text] [Related]
20. Results obtained with prodectin in arteriosclerotic arterial obliteration of the lower extremities.
Hunyi L
Ther Hung; 1976; 24(2):67-71. PubMed ID: 982342
[No Abstract] [Full Text] [Related]
[Next] [New Search]
